4/1/2013

Theraclone Sciences secured an additional $8 million, bringing the total raised in its Series B funding round to $50 million. The Seattle biotech is developing two antibodies for severe flu and cytomegalovirus infection.

Full Story:
MedCityNews.com

Related Summaries